Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma.
Zhang Q, Zhang J, Zhong H, Yuan Y, Yang L, Zhang Q, Ji D, Gong J, Li J, Yao Z, Qi C, Wang J, Lu L, Shi M, Qian X, Shen L, Li J, Hu X.
Zhang Q, et al. Among authors: hu x.
Cancer Immunol Immunother. 2023 Aug;72(8):2729-2739. doi: 10.1007/s00262-023-03434-2. Epub 2023 Apr 28.
Cancer Immunol Immunother. 2023.
PMID: 37115210
Free PMC article.
Clinical Trial.